FDA Approves Ibrutinib for Mantle Cell Lymphoma
The US Food and Drug Administration (FDA) has approved ibrutinib (Imbruvica) to treat some people with mantle cell lymphoma. The drug is intended for patients who have stopped responding to treatment, or whose cancer has come back after treatment.
Drug Shows Promise for Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
Ibrutinib, a new drug under development, is showing promise as a treatment for mantle cell lymphoma and chronic lymphocytic leukemia (CLL), according to new studies.
Study Shows Certain Lymphoma Patients Can Avoid Radiation
Researchers from the National Cancer Institute and Stanford University have found that patients with primary mediastinal B-cell lymphoma can be treated successfully without radiation.
Cancer Can Be Treated During Pregnancy
When a pregnant woman is diagnosed with cancer, her treatment decisions are complicated by concern about how treatment may affect the baby’s health.
FDA Approves Adcetris for Two Types of Lymphoma
The FDA has approved Adcetris (brentuximab vedotin) for Hodgkin disease and systemic anaplastic large-cell lymphoma (ALCL).
Experts See Progress, Hope in Battle Against Childhood Cancers
Survival has improved dramatically for kids with cancer over the past 30 years.
TNF Blockers May Increase Lymphoma Risk in Kids
Kids and teens treated with drugs called tumor necrosis factor (TNF) blockers may be at an increased risk for lymphoma and other cancers, according to the US Food and Drug Administration (FDA), which is updating black box warnings for the drugs.